Skip to main content

Table 1 The Demographic data for the patients and the values for their OCT parameters

From: The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy

 

Mean

SD

Median

Min

Max

P*

Age(years)

44.77

9.08

43.00

31

69

0.649

Male, n (%)

49 (79.0%)

NA

NA

NA

NA

NA

Symptom duration before half-dose PDT (days)

132.05

156.17

69.50

42

784

0.000

BCVA before half-dose PDT (logMAR)

0.30

0.22

0.20

0.00

0.90

0.026

BCVA 12 m after half-dose PDT(logMAR)

0.06

0.14

0.00

0.00

0.70

0.000

CRT(μm)

199.02

110.04

189.50

31.00

468.00

0.910

Half-dose PDT spot size(mm2)

7.57

3.86

6.64

2.69

21.20

0.059

Height of retinal detachment(μm)

284.23

112.86

275.50

98.00

524.00

0.820

Width of subretinal space on horizontal scan (μm)

2958.21

1215.95

2742.50

962.00

7970.00

0.160

Width of subretinal space on vertical scan (μm)

2665.98

1296.03

2398.00

885.00

8566.00

0.068

H/W on horizontal scan

0.10

0.04

0.10

0.03

0.19

0.872

H/W on vertical scan

0.12

0.04

0.11

0.02

0.22

0.723

Difference of foveal ONL thickness (μm)

9.15

8.16

10.00

−8.00

29.00

0.922

  1. BCVA best corrected visual acuity, CRT central retinal thickness, N/A not applicable; H/W the ratio of retinal detachment height to subretinal space width, logMAR logarithm of the minimum angle of resolution; ONL outer nuclear layer, PDT photodynamic therapy, SD standard deviation
  2. *The Kolmogorov–Smirnov test was used to confirm the normality of the data. P ≥ 0.05 indicates that the data are normally distributed, and the mean value is shown in bold. P < 0.05 indicates that the data are not normally distributed, and the median value is shown in bold